ArticleJournal of proteome research2026
Pan-Cell Death Protein Signature as a Novel Diagnostic and Prognostic Biomarker for Intracerebral Hemorrhage.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracerebral hemorrhage (ICH) remains a major cause of morbidity and mortality, with no rapid blood-based biomarkers available to assess secondary brain injury. This study aimed to identify a circulating pan-cell death protein signature for diagnosing and prognosing ICH. We prospectively enrolled 60 ICH patients and 60 age/sex-matched healthy controls, collecting plasma at defined time points after ICH onset. Using Olink proteomics, we identified 13 apoptosis-related proteins with significant dysregulation. Four key proteins─TLR4, ALOX15, FTL, and BMF─were validated through ELISA and RT-qPCR, showing good diagnostic performance (AUCs 0.799-0.835). A multiprotein logistic model demonstrated excellent diagnostic accuracy (AUC = 0.955). These biomarkers correlated with clinical severity and prognosis, including hematoma volume and a 90-day modified Rankin Scale (mRS). Additionally, animal models confirmed time-dependent upregulation of TLR4 in astrocytes. This pan-cell death protein signature provides valuable insights into ICH pathology and offers a promising tool for early diagnosis, risk stratification, and therapeutic targeting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.